R560S: A class II CFTR mutation that is not rescued by current modulators.

[1]  A. Windemuth,et al.  Comprehensive mapping of Cystic Fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site , 2018, bioRxiv.

[2]  A. Ramalho,et al.  mRNA‐based detection of rare CFTR mutations improves genetic diagnosis of cystic fibrosis in populations with high genetic heterogeneity , 2017, Clinical genetics.

[3]  Jue Chen,et al.  Atomic Structure of the Cystic Fibrosis Transmembrane Conductance Regulator , 2016, Cell.

[4]  M. Amaral,et al.  Progress in therapies for cystic fibrosis. , 2016, The Lancet. Respiratory medicine.

[5]  H. Clevers,et al.  Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis , 2016, Science Translational Medicine.

[6]  M. Maiuri,et al.  A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR , 2016, Cell Death and Differentiation.

[7]  A. Heinzmann,et al.  Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. , 2015, American journal of respiratory and critical care medicine.

[8]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[9]  M. Amaral,et al.  Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR , 2015, Pharmacology research & perspectives.

[10]  H. Janssens,et al.  A bioassay using intestinal organoids to measure CFTR modulators in human plasma. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[11]  Nikhil T. Awatade,et al.  Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis , 2014, EBioMedicine.

[12]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[13]  M. Maiuri,et al.  Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation , 2014, Autophagy.

[14]  George P Patrinos,et al.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.

[15]  Marisa Sousa,et al.  Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. , 2013, Chemistry & biology.

[16]  H. Clevers,et al.  Growing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications , 2013, Science.

[17]  Hans Clevers,et al.  A functional CFTR assay using primary cystic fibrosis intestinal organoids , 2013, Nature Medicine.

[18]  M. Amaral,et al.  Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility , 2013, BMC Gastroenterology.

[19]  M. Amaral,et al.  Control of TMEM16A by INO‐4995 and other inositolphosphates , 2013, British journal of pharmacology.

[20]  M. Amaral,et al.  Measurements of CFTR-Mediated Cl− Secretion in Human Rectal Biopsies Constitute a Robust Biomarker for Cystic Fibrosis Diagnosis and Prognosis , 2012, PloS one.

[21]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[22]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[23]  D. Cyr,et al.  Mechanisms for rescue of correctable folding defects in CFTRDelta F508. , 2009, Molecular biology of the cell.

[24]  P. Negulescu,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[25]  C. Soares,et al.  Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms , 2006, Proceedings of the National Academy of Sciences.

[26]  M. Amaral,et al.  CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. , 2004, Gastroenterology.

[27]  M. Amaral,et al.  Unusually common cystic fibrosis mutation in Portugal encodes a misprocessed protein. , 2003, Biochemical and biophysical research communications.

[28]  Teresa Casals,et al.  New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12. , 2003, Human molecular genetics.

[29]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[30]  R. Kraemer,et al.  Two buffer PAGE system-based SSCP/HD analysis: a general protocol for rapid and sensitive mutation screening in cystic fibrosis and any other human genetic disease , 1999, European Journal of Human Genetics.

[31]  L. Clarke,et al.  Comparative ex vivo, in vitro and in silico analyses of a CFTR splicing mutation: Importance of functional studies to establish disease liability of mutations. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[32]  J. Elborn,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[33]  F. van Goor,et al.  Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[34]  P. Robinson.  Cystic fibrosis , 2001 .

[35]  M. Welsh,et al.  Structure and function of the CFTR chloride channel. , 1999, Physiological reviews.

[36]  M. Schwarz,et al.  Detection of five novel mutations of the cystic fibrosis transmembrane regulator (CFTR) gene in Pakistani patients with cystic fibrosis: Y569D, Q98X, 296+12(T>C), 1161delC and 621+2(T>C) , 1998, Human mutation.

[37]  L. Chin,et al.  CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. , 1994, American journal of respiratory cell and molecular biology.